EUVIMEDEUVIMED entdecken
Open Access

Association of Serum Hepatocyte Growth Factor Level with Systemic Inflammatory Biomarkers in Patients with Pancreatobiliary Cancer

İlkay Tuğba Ünek, İlhan Öztop, Yasemin Başbınar, Tarkan Ünek, Asım Leblebici, Ece Çakıroğlu, Tuğba Uysal, Baran Akagündüz, Hülya Ellidokuz, İbrahim Astarcıoğlu

Turkish Journal of Gastroenterology · 2023

DOI: 10.5152/tjg.2023.22124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Turkish Journal of Gastroenterology, 2023. Verfasst von İlkay Tuğba Ünek und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey. Hauptthemen laut MEDLINE: Hepatocyte Growth Factor, Gastrointestinal Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocyte growth factor is a cytokine secreted by the stromal cells in the tumor microenvironment. There is little information about the clinical significance of serum hepatocyte growth factor level in patients diagnosed with pancreatobiliary cancer. The objective of the current study was to investigate the relationship between serum hepatocyte growth factor level with inflammation markers and the clinical features of patients with pancreatobiliary cancer.

Methods

A total of 62 patients with pancreatobiliary cancer were included in this study. Serum hepatocyte growth factor concentrations were evaluated utilizing the enzyme-linked immunosorbent assay method.

Results

The median serum hepatocyte growth factor level was 329.1 ng/mL (1.4-1051.1). The patients were categorized into 2 groups as those below the median hepatocyte growth factor level (low hepatocyte growth factor) and those above the median hepatocyte growth factor level (high hepatocyte growth factor). While 40.9% of the patients without metastasis were observed to be in the high hepatocyte growth factor group, 72.2% of the metastatic patients were observed to be in the high hepatocyte growth factor group (P = .025). The median levels of monocyte, monocyte-to-lymphocyte ratio, C-reactive protein, and C-reactive protein-to-albumin ratio were found to be significantly higher in the high hepatocyte growth factor group as compared to the low hepatocyte growth factor group (P < .050).

Conclusion

The significant relationship between serum hepatocyte growth factor level and systemic inflammation markers in patients with pancreatobiliary cancer is shown for the first time in our study. This study, which showed a significant relationship between the presence of metastasis and serum hepatocyte growth factor level, suggests that serum hepatocyte growth factor level may be a prognostic biomarker in patients who are diagnosed with pancreatobiliary cancer. Cite this article as: Ünek İT, Öztop İ, Başbınar Y, et al. Association of serum hepatocyte growth factor level with systemic inflammatory biomarkers in patients with pancreatobiliary cancer. Turk J Gastroenterol. 2023;34(5):568-575.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatocyte Growth FactorGastrointestinal NeoplasmsHumansC-Reactive ProteinBiomarkersInflammationBiomarkers, TumorPrognosisTumor Microenvironment

Substanzen

Hepatocyte Growth FactorC-Reactive ProteinBiomarkersBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey.
  • Department of Translational Oncology, Dokuz Eylül University, Institute of Oncology, İzmir, Turkey.
  • Department of General Surgery, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey.
  • Department of Translational Oncology, Dokuz Eylül University, Institute of Health Sciences, İzmir, Turkey.
  • Department of Genomics and Molecular Biotechnology, Dokuz Eylül University, İzmir International Biomedicine and Genome Institute, İzmir, Turkey.
  • Department of Molecular Biology and Genetics, Hitit University Faculty of Science and Art, Çorum, Turkey.

Zitieren

APA

Ünek, İ. T., Öztop, İ., Başbınar, Y., Ünek, T., Leblebici, A., Çakıroğlu, E., Uysal, T., Akagündüz, B., Ellidokuz, H., & Astarcıoğlu, İ. (2023). Association of Serum Hepatocyte Growth Factor Level with Systemic Inflammatory Biomarkers in Patients with Pancreatobiliary Cancer. Turkish Journal of Gastroenterology. https://doi.org/10.5152/tjg.2023.22124

Vancouver

Ünek İT, Öztop İ, Başbınar Y, Ünek T, Leblebici A, Çakıroğlu E, et al. Association of Serum Hepatocyte Growth Factor Level with Systemic Inflammatory Biomarkers in Patients with Pancreatobiliary Cancer. Turkish Journal of Gastroenterology. 2023. doi:10.5152/tjg.2023.22124

BibTeX
@article{nek2023,
  author = {Ünek, İlkay Tuğba and Öztop, İlhan and Başbınar, Yasemin and Ünek, Tarkan and Leblebici, Asım and Çakıroğlu, Ece and Uysal, Tuğba and Akagündüz, Baran and Ellidokuz, Hülya and Astarcıoğlu, İbrahim},
  title = {Association of Serum Hepatocyte Growth Factor Level with Systemic Inflammatory Biomarkers in Patients with Pancreatobiliary Cancer},
  journal = {Turkish Journal of Gastroenterology},
  year = {2023},
  doi = {10.5152/tjg.2023.22124}
}
Kostenlos starten →